Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Related Citations for PubMed (Select 20147655)

1.

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB.

Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF.

Neurology. 2010 Mar 9;74(10):807-15. doi: 10.1212/WNL.0b013e3181d3e3e9. Epub 2010 Feb 10.

2.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

3.

Longitudinal patterns of β-amyloid deposition in nondemented older adults.

Sojkova J, Zhou Y, An Y, Kraut MA, Ferrucci L, Wong DF, Resnick SM.

Arch Neurol. 2011 May;68(5):644-9. doi: 10.1001/archneurol.2011.77.

4.

The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.

Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ.

Alzheimers Dement. 2013 Nov;9(6):687-698.e1. doi: 10.1016/j.jalz.2012.10.012. Epub 2013 Mar 7.

5.

The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction.

Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, DeCarli C, Weiner MW, Mungas DM, Chui HC, Jagust WJ.

JAMA Neurol. 2013 Apr;70(4):488-95. doi: 10.1001/2013.jamaneurol.405.

6.

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.

Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ.

J Neurosci. 2013 Mar 27;33(13):5553-63. doi: 10.1523/JNEUROSCI.4409-12.2013.

7.

Association of lifetime cognitive engagement and low β-amyloid deposition.

Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, Wilson RS, Jagust WJ.

Arch Neurol. 2012 May;69(5):623-29.

8.
9.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
10.

Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.

Koivunen J, Karrasch M, Scheinin NM, Aalto S, Vahlberg T, Någren K, Helin S, Viitanen M, Rinne JO.

Dement Geriatr Cogn Disord. 2012;34(1):31-7. doi: 10.1159/000341580. Epub 2012 Aug 3.

PMID:
22868352
11.

Imaging beta-amyloid burden in aging and dementia.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL.

Neurology. 2007 May 15;68(20):1718-25.

PMID:
17502554
12.

Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals.

Driscoll I, Zhou Y, An Y, Sojkova J, Davatzikos C, Kraut MA, Ye W, Ferrucci L, Mathis CA, Klunk WE, Wong DF, Resnick SM.

Neurobiol Aging. 2011 Dec;32(12):2123-30. doi: 10.1016/j.neurobiolaging.2009.12.008. Epub 2010 Feb 21.

13.

Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.

Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, Pimlott S, Hutchinson PJ, Tavares A, Canales R, Mathis CA, Klunk WE, Aigbirhio FI, Coles JP, Baron JC, Pickard JD, Fryer TD, Stewart W, Menon DK.

JAMA Neurol. 2014 Jan;71(1):23-31. doi: 10.1001/jamaneurol.2013.4847.

14.

Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.

Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ.

Arch Neurol. 2012 Feb;69(2):223-9. doi: 10.1001/archneurol.2011.666.

15.

Amyloid imaging of Lewy body-associated disorders.

Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, Hershey T, Perlmutter JS.

Mov Disord. 2010 Nov 15;25(15):2516-23. doi: 10.1002/mds.23393.

16.

Fibrillar amyloid correlates of preclinical cognitive decline.

Stonnington CM, Chen K, Lee W, Locke DE, Dueck AC, Liu X, Roontiva A, Fleisher AS, Caselli RJ, Reiman EM.

Alzheimers Dement. 2014 Jan;10(1):e1-8. doi: 10.1016/j.jalz.2013.01.009. Epub 2013 Apr 11.

17.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

18.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

19.

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC.

Ann Neurol. 2011 Jan;69(1):181-92. doi: 10.1002/ana.22248.

20.

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA.

Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk